Regeneration-Inducing Medicine Redasemtide Closes Refractory Ulcers in Phase 2 Trial, Misses Stroke Endpoint

For a regenerative therapy to work without requiring a transplant of living cells, a binding constraint must be met: the drug must successfully signal the patient's own bone marrow to release mesenchymal stem cells and guide them through the bloodstream to the exact site of injury.

That mechanism—the core premise of a new class of "regeneration-inducing medicines"—has just demonstrated its clinical viability in a rare skin disease, even as it failed to reverse neurological damage in a much larger stroke trial. On September 9, 2026, Japanese pharmaceutical company Shionogi and biotech partner StemRIM announced split Phase 2 results for redasemtide, a peptide designed to trigger this exact endogenous repair process.[1][5]

The most definitive success emerged from a small, targeted Phase 2 trial in dystrophic epidermolysis bullosa (DEB), a severe genetic dermatosis characterized by extreme skin fragility and chronic blistering. Because the disease impairs the structural integrity of the skin, patients often develop intractable wounds that remain open for years. In the trial, redasemtide met its primary endpoint, achieving the complete closure of refractory ulcers in three out of four treated patients.[1][5]

"In addition, in certain cases, favorable results were also observed for clinical symptoms, including the total body ulcer area," Shionogi noted in its clinical update, confirming that the drug exhibited a favorable tolerability profile with no new safety concerns. The results offer a potential systemic intervention for a condition that currently relies heavily on localized wound care and pain management. Shionogi estimates that between 500 and 1,000 people in Japan live with epidermolysis bullosa in all its forms, with the dystrophic variant accounting for roughly half of those cases.[1]

Redasemtide, designated internally as S-005151, operates differently from traditional cell therapies. Rather than manufacturing and infusing exogenous stem cells, the drug is a peptide derived from High Mobility Group Box 1 (HMGB1), a nuclear protein. When administered, it acts as a systemic distress signal, mobilizing the body's latent mesenchymal stem cells from the bone marrow and directing them to accumulate at the site of damaged tissue to accelerate healing.[1][2]

While that mechanism proved capable of closing skin ulcers, it struggled to overcome the complex neural damage of an acute ischemic stroke. In a global Phase 2b trial enrolling 627 patients aged 18 years or older, redasemtide failed to meet its primary endpoint. The study evaluated patients who were administered either a 0.75 mg/kg or 1.5 mg/kg dose of the drug, or a placebo, for five consecutive days, with treatment initiating within 25 hours of stroke onset.[1][3][4]

The stroke trial's primary efficacy measure was the modified Rankin Scale (mRS)—a standard clinical metric evaluating the degree of disability and dependence in daily activities—assessed at 90 days post-administration. In the specific cohort of patients who did not undergo endovascular recanalization therapy to physically remove the clot, the redasemtide group did not demonstrate a statistically significant improvement over the placebo group.[1][4]

Despite the formal miss, the developers pointed to secondary signals within the data. Shionogi reported that an exploratory subgroup analysis suggested a trend toward improvement on the mRS for patients who presented with higher severity at the time of onset. This observation mirrors the findings of an earlier 150-patient Phase 2 trial conducted exclusively in Japan, which had previously shown an increase in the rate of patients returning to a socially independent level.[1][2]

The divergence in redasemtide's efficacy highlights the biological realities of tissue regeneration. The skin is a highly dynamic organ with an established, rapid cellular turnover process, making it inherently receptive to stem cell-mediated repair. In contrast, the central nervous system presents a formidable regenerative barrier; ischemic strokes cause immediate, localized necrosis of highly specialized neurons and disrupt intricate neural networks that are notoriously difficult to rebuild once the initial 24-hour window closes.[6]

The market and clinical focus now shift to how Shionogi will allocate its resources. The company stated it will conduct a deeper analysis of the 627-patient stroke dataset before deciding whether to advance the indication into a definitive Phase 3 trial. Meanwhile, discussions with StemRIM are accelerating to push the epidermolysis bullosa program forward, capitalizing on the orphan drug designation granted by the Japanese Ministry of Health, Labor and Welfare.[2][4]

The clinical and commercial viability of the regeneration-inducing medicine platform hinges on these next regulatory steps. StemRIM and Shionogi are concurrently testing redasemtide in chronic liver disease, knee osteoarthritis, and cardiomyopathy. The upcoming decision on whether to abandon the stroke indication entirely or narrow the target population to the most severe cases will dictate whether endogenous stem cell mobilization becomes a broad-spectrum medical tool or a highly specialized intervention for peripheral tissue repair.[1][2]